Characteristics of early pregnancy and prevention of gestational and perinatal complications in women with metabolic syndrome

Introduction. Based on the knowledge of early gestational disorders related to metabolic syndrome (MS), pathogenetically relevant preventive treatment meeting the requirements of perinatal pharmacology can be developed.

Aim. To reveal clinical and laboratory characteristics of early pregnancy and develop pathogenetically relevant preventive monotherapy for unfavorable gestational and perinatal outcomes in women with metabolic syndrome.

Material and methods. A total of 230 women were investigated and divided into four groups: Group I consisted of 68 pregnant women with MS who refused any preventive measures; Group II comprised 97 women with MS who received periconceptional preventive monotherapy with dydrogesterone, a progestagen; Group III consisted of 35 healthy primigravidas women with physiological course of gestation; Group IV comprised 30 healthy non-pregnant women. Laboratory testing during I–III trimesters allowed to assess the dynamics demonstrated by markers of lipid spectrum, endothelial dysfunction, apoptosis, decidualization, energy metabolism, and immunomodulation.

Results. A balance between factors of physiological damage and gestational adaptation in the course of physiological pregnancy has been shown to be of primary significance. In women with MS, embryo-placental dysfunction develops during early pregnancy, and this stage is preceding for major obstetric syndromes. Preventive administration of dydrogesterone in women with MS appeared highly effective: NNT (number needed to treat) was 1.33 (95% CI 0.9–1.8); OR 5.2 (95% CI 4.6–5.7).

Conclusion. Pregestational changes and atherogenic profile of gestational process determine the course of early pregnancy in women with MS with the development of embryo-placental dysfunction and major obstetric syndromes. High efficacy in the prevention of unfavorable gestational and perinatal outcomes was shown by preventive dydrogesterone monotherapy.

metabolic syndrome, early gestation, preventive treatment with dydrogesterone, standards of evidence-based medicine

1. Леваков С.А., Боровкова Е.И. Беременность на фоне ожирения и метаболического синдрома // Вопросы гинекологии, акушерства и перинатологии. – 2014. – Т.13. – № 5. – С. 5-10. [Levakov SA, Borovkova EI. Pregnancy against the background of obesity and metabolic syndrome. Voprosy ginekologii, akusherstva i perinatologii. 2014;13(5):5-10. (In Russ.)]

2. Липатов И.С., Тезиков Ю.В., Стулова С.В., и др. Маркеры иммунного воспаления сосудистой стенки у беременных с метаболическим синдромом // Эфферентная терапия. – 2007. – Т.13. – № 1. – С. 98. [Lipatov IS, Tezikov YuV, Stulova SV, et al. Markery immunnogo vospaleniya sosudistoi stenki u beremennykh s metabolicheskim sindromom. Efferentnaya terapiya. 2007;13(1):98. (In Russ.)]

3. Савельева И.В. Клиническое течение беременности при метаболическом синдроме // Омский научный вестник. – 2012. – Т. 1. – № 108. – С. 56-59. [Savelyeva IV. Clinical course of pregnancy under metabolic syndrome. Omskii nauchnyi vestnik. 2012;1(108):56-59. (In Russ.)]

4. Макаров И.О., Боровкова Е.И., Казаков Р.Д. Характер метаболических изменений у беременных с ожирением // Российский вестник акушера-гинеколога. – 2013. – Т.13. – № 3. – С. 38-41. [Makarov IO, Borovkova EI, Kazakov RD. The pattern of metabolic changes in pregnant women with obesity. Rossiiskii vestnik akushera-ginekologa. 2013;13(3):38-41]

5. Тезиков Ю.В., Липатов И.С., Фролова Н.А., и др. Методология профилактики больших акушерских синдромов // Вопросы гинекологии, акушерства и перинатологии. – 2016. – Т.16. – № 1. – С. 57-64. [Tezikov YuV, Lipatov IS, Frolova NA, et al. Metodologiya profilaktiki bol'shikh akusherskikh sindromov. Voprosy ginekologii, akusherstva i perinatologii. 2016;16(1): 57-64. (In Russ.)]

6. Тезиков Ю.В., Липатов И.С., Стулова С.В., Есартия М.А. // Эфферентная терапия. – 2012. – Т.18. – № 1. – С. 122. [Tezikov YuV, Lipatov IS, Stulova SV, Esartiya MA. Profilaktika i lechenie narushenii laktatsii u zhenshchin s metabolicheskim sindromom s ispol'zovaniem vidimogo i infrakrasnogo polyarizovannogo sveta. Efferentnaya terapiya. 2012;18(1):122. (In Russ.)]

7. Тезиков Ю.В., Липатов И.С., Фролова Н.А., и др. Информативность предикторов больших акушерских синдромов у беременных с эмбриоплацентарной дисфункцией // Аспирантский вестник Поволжья. – 2015. – Т. 5-6. – № 1. – С. 48-55. [Tezikov YuV, Lipatov IS, Frolova NA, et al. Informativnost' prediktorov bol'shikh akusherskikh sindromov u beremennykh s embrioplatsentarnoi disfunktsiei. Aspirantskii vestnik Povolzh'ya. 2015;5-6(1):48-55. (In Russ.)]

8. Дындарь Е.А., Бенюк В.А. Особенности состояния фетоплацентарного комплекса у женщин с невынашиванием беременности на фоне избыточной массы тела и метаболического синдрома // Перинатология и педиатрия. – 2015. – № 1. – С. 28. [Dyndar' E.A., Benyuk V.A. The features of the state of fetoplacental complex at women with miscarriage due to the overweight and metabolic syndrome. Perinatologiya i pediatriya. 2015;(1):28. (In Russ.)]

9. Banoo E, Sharifi F, Badamchizaden Z, Hossein-Nezhad A, et al. Association of metabolic syndrome with inflammatory mediators in women with previous gestational diabetes mellitus. Journal of Diabetes & Metabolic Disorders. 2013;12:8. doi: 10.1186/2251-6581-12-8.

10. Передеряева Е.Б., Пшеничникова Т.Б. Противотромботическая профилактика повторных осложнений беременности у женщин с метаболическим синдромом и тромбофилией // Акушерство, гинекология и репродукция. – 2014. – Т.8. – №4. – С. 80-81. [Perederyaeva EB, Pshenichnikova TB. Protivotromboticheskaya profilaktika povtornykh oslozhnenii beremennosti u zhenshchin s metabolicheskim sindromom i trombofiliei. Akusherstvo, ginekologiya i reproduktsiya. 2014;8(4): 80-81. (In Russ.)]

11. Walsh JM, McGowan CA, Byrne JA, Rath A, et al. The association between TNF-a and insulin resistance in englycemic women. Citokine. 2013;64(1):208-212. doi: 10.1016/j.cyto.2013.07.001.

12. Палиева Н.В., Боташева Т.Л., Линде В.А., и др. Особенности про- и контринсулярных факторов у беременных с метаболическим синдромом в зависимости от морфофункциональных асимметрий маточно-плацентарного комплекса // Таврический медико-биологический вестник. – 2016. – Т.19. – №2. – С. 113-118. [Palieva NV, Botasheva TL, Linde VA, et al. Osobennosti pro- i kontrinsulyarnykh faktorov u beremennykh s metabolicheskim sindromom v zavisimosti ot morfofunktsional'nykh asimmetrii matochno-platsentarnogo kompleksa. Tavricheskii mediko-biologicheskii vestnik. 2016;19(2):113-118. (In Russ.)]